The collection breaks the traditional boundary of volume price growth, but the sales volume released by it may not be able to offset the impact of
price reduction.
Therefore, in this context, hedging the impact of collection, finding new profit growth points, and actively adjusting the business structure have also become the top priority
for the development of many pharmaceutical companies.
Among them, it is worth noting that with the acceleration of the adjustment of the organizational structure of enterprises, many enterprises have carried out measures such as splitting and divestiture, business integration, replacement of senior executives, and scale layoffs
.
Under the intensive adjustment of major pharmaceutical companies, innovation is occupying an increasingly important position (Image source: Pharmaceutical Network)
For example, Sanofi China announced new personnel appointments in the first half of the year: from August 1, Sanofi China will be headed by Shi Wang as the head of China and the head of the Greater China region of the general pharmaceutical business unit
.
Schwann will lead the acceleration of the transformation of the market for Sanofi's innovative insulin products Soliqua and cardiovascular drug Praluent, as well as the implementation of the Volume Procurement (VBP) strategy
for the new generation of basal insulin Toujeo.
Since June 2021, when two heavy products in the respiratory field were not included in the collection, AstraZeneca's structural adjustments in the Chinese market have become particularly frequent, including the merger of the existing digestion and respiratory atomization business in June 2021 to establish the digestion and respiratory atomization business unit; In September 2021, the Rare Diseases Business Unit was officially established; By November, it was announced that it would split and merge multiple business units.
.
.
Today, AstraZeneca China has formed four business structures
: Oncology Division, Respiratory, Digestive and Autoimmune Division, Cardiovascular, Renal and Metabolic Division, and Rare Disease Division.
In the industry's view, whether it is structural adjustment or personnel changes, multinational pharmaceutical companies are to better adapt to changes in the Chinese pharmaceutical market environment and focus on core business, especially in the field of
innovative drugs.
From the current strategic adjustment of most multinational pharmaceutical companies, it is not difficult to see that innovation occupies a prominent position
.
In fact, in addition to multinational pharmaceutical companies, domestic pharmaceutical companies have also adjusted continuously
under the impetus of collection and procurement.
Among them, the innovation of the increased layout has long become the trend of the times
.
It is understood that in recent years, the investment in innovation and research and development of local pharmaceutical companies has been rising continuously
.
Among them, the average annual growth rate of R&D investment of large-scale enterprises is about 8%, and the R&D expenses of listed companies will account for more than 6%
of sales revenue in 2020.
At present, under the continuous investment in innovative research and development, many enterprises have also ushered in results
.
On August 23, the 2022 interim performance report released by China Biopharmaceutical showed that new products, innovative drugs and tumor drugs have become its second growth curve, effectively hedging the impact of the first three batches of collection - of which 84 new products have been listed in the past 5 years, accounting for 43.
5%
of revenue.
It is worth noting that while pharmaceutical companies are increasing the field of innovative drugs, many pharmaceutical companies are still streamlining personnel and expenditures; As well as embracing digitalization to accelerate transformation and upgrading and improve market competitiveness
.
In this regard, the industry believes that with the continuous deepening of collection and procurement, pharmaceutical companies will take a more diversified approach to enhance competitiveness and seize opportunities
while strengthening investment in research and development and creating a more reasonable personnel structure.
In general, in recent years, the pharmaceutical industry has introduced a series of policies such as generic drug consistency evaluation, collection, medical insurance control fees, and key monitoring of auxiliary drugs, which have squeezed the profit margins of pharmaceutical companies and accelerated the reshuffle
of the entire market.
In the future, in this context, major pharmaceutical companies will have to rely on innovative drugs
if they want to seek development.
However, it should be noted that due to this impact, the competition of major pharmaceutical companies in the field of innovation will continue to intensify
in the future.
